Kimberly L. Hallowell

Kimberly L. Hallowell

Auto-generated profile, based on publicly available information

Kimberly L. Hallowell

Department of Clinical Sciences, College of Veterinary Medicine North Carolina State University Raleigh North Carolina USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2024 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
KHKimberly L. Hallowell
Kimberly L. Hallowell
KHKate L. Hepworth-Warren
Kate L. Hepworth-Warren
KDKatarzyna Dembek
Katarzyna Dembek
Background: Available descriptive studies on equine pneumonia are outdated or focus on specific horse or bacterial populations. Objectives: To describe the clinical presentation and bacterial isolates of adult horses with bacterial pneumonia and identify factors associated with death. Animals: One hundred sixteen horses >2 years old with bacterial pneumonia. Methods: Retrospective case series. Data regarding history, physical examination, clinicopathologic features, treatment, bacterial culture and sensitivity, and outcome were collected and analyzed retrospectively. Results: Historical risk factors were present for 60% of cases, whereas abnormal vital signs on intake were present for <50%. Most horses (58%) underwent at least 1 change of antimicrobial treatment, and 67% received the highest-priority critically important antimicrobials. Streptococcus zooepidemicus was the most isolated bacteria (44%), followed by Escherichia coli (19%), Klebsiella spp. (18%), other Streptococcus species (17%), and Bacillus spp. (13%). Fusobacterium spp. were the most common anaerobic isolates (11%). Antimicrobial susceptibility varied widely. Survival to discharge was 73%. Heart rate at presentation (odds ratio [OR] 1.08, 95% confidence interval [CI] 1.008-1.17, P = .03) and higher creatinine (OR 14.1, 95% CI 1.56-127.6, P = .02) increased the risk of death. Higher lymphocyte count (OR 0.27, 95% CI 0.08-0.94, P = .04) reduced risk. Conclusions and Clinical Importance: Contrasting older literature, Fusobacterium spp. were the most common anaerobes. Streptococcus zooepidemicus remained the most common isolate and was predictably susceptible to penicillin. Antimicrobial susceptibility was otherwise variable and broad applicability is limited as this was a single-center study. Increased risk of death associated with tachycardia and abnormally high serum creatinine concentration is consistent with previous studies.

1 September 2024 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
Kallie HobbsKallie Hobbs
Kallie Hobbs
ASAndre N. V. Le Sueur
Andre N. V. Le Sueur
KHKimberly Hallowell
Kimberly Hallowell
EMEmily Martin
Emily Martin
M. Katie SheatsM. Katie Sheats
M. Katie Sheats
YUYu Ueda
Yu Ueda
An 8-year-old American Quarter Horse gelding was treated with extracorporeal hemoperfusion (HP) therapy for treatment of Clostridioides difficile (C. difficile) colitis-induced systemic inflammatory response syndrome (SIRS). The gelding developed C. difficile associated peracute colitis and severe SIRS as evidenced by a positive fecal C. difficile PCR and tachypnea, tachycardia, fever, neutropenia, altered mucous membrane color, and hyperlactatemia. Concurrent acute kidney injury in the horse limited the use of routine anti-inflammatory and anti-lipopolysaccharide treatments, including flunixin meglumine and polymyxin B, because of potential for nephrosis. Extracorporeal HP therapy was performed twice within 48 hours of the onset of severe SIRS during which the horse's physical examination variables stabilized. The horse was euthanized after 4 days because of laminitis. These findings support further investigation of extracorporeal HP therapy as an adjunctive treatment for severe SIRS/sepsis in horses.

1 July 2026 in Equine Veterinary Journal
Verified
Journal Article
Open access
KHKimberly L. Hallowell
Kimberly L. Hallowell
CHCaitlyn R. Horne
Caitlyn R. Horne
CMCary S. Miller
Cary S. Miller
STSara R. Tufts
Sara R. Tufts
KDKatarzyna Dembek
Katarzyna Dembek
LSLauren V Schnabel
Lauren V Schnabel
Background: The prevalence of insulin dysregulation (ID) has not been investigated in sport horses. Stall‐side insulin assays offer convenience but need further validation. Objectives: To determine the prevalence of and risk factors for ID in a sport horse population using an oral sugar test (OST) and assess agreement between stall‐side and validated laboratory assays for insulin quantification. Study Design: Prospective cross‐sectional study. Methods: One hundred eighty sport horses presenting for orthopaedic evaluation at a university hospital ( N = 140) or local farms ( N = 40) were tested for ID using OST (0.15 mL/kg light corn syrup). Morphometric data were collected, and baseline serum leptin and adiponectin concentrations were measured. Insulin concentrations were measured using the validated fluorescence enzyme immunoassay (FEIA) and a stall‐side lateral flow assay (LFA). ID was diagnosed if FEIA insulin measured >20 μIU/mL at T0 or >30 μIU/mL at T60/T90. Factors associated with ID were assessed using a mixed effects binary logistic regression model. Assay agreement was assessed using Pearson's correlation coefficient and Bland–Altman plot. Receiver operator characteristic curve analysis was performed to determine diagnostic cut‐offs for LFA. Results: ID was diagnosed in 22.8% (41/180) of horses. Only 11/41 ID horses had increased fasted insulin. Increasing leptin/adiponectin ratio in males was the only significant predictor of ID (OR = 1.102, 95% CI 1.036–1.171). Correlation between FEIA and LFA insulin measures was good ( r = 0.81, 95% CI 0.78–0.84), but the LFA read on average 13.62 μIU/mL higher than the FEIA and had greater variability at higher insulin concentrations. Area under the ROC curve showed the LFA was excellent at correctly classifying ID status (AUC = 0.95, 95% CI 0.93–0.97). Main Limitations: Single‐centre study, voluntary enrolment may overestimate ID prevalence. Conclusions: ID is common in sport horses and often requires dynamic insulin testing to diagnose. Physical appearance does not predict ID risk. Agreement between stall‐side and laboratory assays is good.

16 February 2026 in Veterinary Clinical Pathology
Verified
Journal Article
Open access
KHKimberly L. Hallowell
Kimberly L. Hallowell
AEAndrew Van Eps
Andrew Van Eps
JKJeaneen C. Kulp
Jeaneen C. Kulp
LSLauren V Schnabel
Lauren V Schnabel
Background: Lipemia is a common comorbidity in horses with obesity or equine metabolic syndrome, but the impact of lipemia on the measurement of insulin and adiponectin has not been evaluated. Objective: To evaluate endogenous and exogenous lipemic interference with equine insulin and adiponectin measurements via several commercial assays. Methods: Endogenous lipemia was evaluated using plasma and serum samples with triglyceride concentrations of < 40, 40–250, 250–500, 500–1000, and > 1000 mg/dL ( n = 6 each). Sample insulin concentrations were determined via fluorescence enzyme immunoassay (FEIA), ELISA, and lateral flow assay (LFA). Test agreement was assessed using Pearson's correlation coefficient, Passing‐Bablok regression, and Bland–Altman analysis. Exogenous lipemia was evaluated using pools of serum, plasma, and whole blood ( n = 5 each) spiked with Intralipid 20% to triglyceride concentrations of 0, 50, 100, 250, 500, and 1000 mg/dL. Insulin concentrations were measured via FEIA, ELISA, and LFA, and adiponectin concentrations via immunoturbidometric assay (ITA). Interferograms were created and a Kruskal–Wallis test was used to compare bias between triglyceride concentrations. Results: With endogenous lipemia, agreement between the three assays was excellent ( r > 0.90) with no appreciable impact of triglyceride concentration. For exogenous lipemia, significant ( p < 0.05) negative interference was observed at triglyceride concentrations of 1000 mg/dL with the insulin ELISA using plasma. No significant interference was found for the insulin ELISA or FEIA using serum, insulin LFA using whole blood or plasma, or adiponectin ITA using serum. Conclusion: Falsely low insulin values may be obtained at high triglyceride concentrations with the insulin ELISA using plasma.

18 September 2026 in The Veterinary Journal
Verified
Journal Article
Open access
KHKate L. Hepworth-Warren
Kate L. Hepworth-Warren
JPJavier Perez-Quesada
Javier Perez-Quesada
KHKaitlyn Harbor
Kaitlyn Harbor
YQYang Qu
Yang Qu
KHKimberly L. Hallowell
Kimberly L. Hallowell
MBMegan E. Ballou
Megan E. Ballou

11 June 2026 in Equine Veterinary Education
Verified
Journal Article
Open access
KTKayden Tanner
Kayden Tanner
LBLuke D. Bass
Luke D. Bass
CKChris Kawcak
Chris Kawcak
LSLauren V Schnabel
Lauren V Schnabel
KHK. L. Hallowell
K. L. Hallowell
LPLynn M. Pezzanite
Lynn M. Pezzanite
Summary: Intra‐articular (IA) corticosteroid administration in equine athletes has gained increased attention recently, particularly in racing. Despite widespread corticosteroid use in equine practice for decades, there are still a lack of equine‐specific studies to address key questions related to their use. Extrapolation of best practices from human literature supports that while IA corticosteroids elicit transient symptom‐modification of osteoarthritis (OA), they can have deleterious effects on articular cartilage depending on drug selection, dose and time‐ indicating the lowest efficacious dose should be used to achieve clinical benefit. While there are limited data supporting current clinical protocols related to dose or injection frequency diminishing returns have been noted with multiple‐injection protocols. Recent studies have led to heightened awareness of equine endocrinopathies and the sensitivity of equine patients with those disorders to the effects of steroids, putting them at increased risk for complications such as laminitis and secondary infection. These findings prompt reconsideration of long‐term or high‐dose corticosteroid administration, particularly given the evolution of alternative IA orthobiologic and immunomodulatory therapies for OA, which require further investigation and comparison for relative modification of clinical signs and disease progression. As much of the referenced literature does not permit direct comparisons across studies, further research is needed to compare corticosteroids at equivalent body doses and dosing intervals in horses with and without endocrinopathies. Without such studies, definitive evidence linking IA corticosteroid use to laminitis risk, subchondral bone injury or catastrophic injury is lacking at this time. This narrative review seeks to summarise the current literature available as well as gaps in knowledge on equine IA corticosteroid use for the practising clinician.